Kirby McInerney LLP is investigating potential federal securities-law claims involving EyePoint Pharmaceuticals and members of its senior management after DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO trial for wet age-related macular degeneration. EyePoint released topline results on Aug. 14, 2026, showing that the treatment failed to achieve the required change in best-corrected visual acuity versus on-label aflibercept. The company’s stock fell $9.88, or 67%, to close at $4.87 on Aug. 17. The investigation follows earlier statements by President and CEO Jay S. Duker expressing confidence and optimism about the trial results. No lawsuit has been filed, and Kirby McInerney said its investigation remains ongoing. Investors who acquired EyePoint securities, suffered losses or have relevant information can contact Lauren Molinaro at no cost.